The stock of Viewray Inc (NASDAQ:VRAY) hit a new 52-week low and has $2.37 target or 14.00% below today’s $2.75 share price. The 6 months bearish chart indicates high risk for the $120.95 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $2.37 price target is reached, the company will be worth $16.93 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 54,907 shares traded hands. Viewray Inc (NASDAQ:VRAY) has declined 27.15% since March 28, 2016 and is downtrending. It has underperformed by 31.87% the S&P500.
Analysts await Viewray Inc (NASDAQ:VRAY) to report earnings on November, 14. They expect $-0.28 EPS, up 20.00% or $0.07 from last year’s $-0.35 per share. After $-0.32 actual EPS reported by Viewray Inc for the previous quarter, Wall Street now forecasts -12.50% EPS growth.
According to Zacks Investment Research, “ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio.”
More notable recent Viewray Inc (NASDAQ:VRAY) news were published by: Prnewswire.com which released: “ViewRay® Appoints Ajay Bansal as Chief Financial Officer” on June 09, 2016, also Crainscleveland.com with their article: “ViewRay Inc. approved to list its stock on the NASDAQ Global Market” published on March 29, 2016, Crainscleveland.com published: “ViewRay Inc. secures $30 million in fresh financing” on December 17, 2013. More interesting news about Viewray Inc (NASDAQ:VRAY) were released by: Crainscleveland.com and their article: “ViewRay Inc. files to raise up to $69 million in initial public offering” published on March 06, 2015 as well as Prnewswire.com‘s news article titled: “ViewRay Completes Alternative Public Offering, Raises $26.7 Million” with publication date: July 23, 2015.
VRAY Company Profile
ViewRay, Inc., incorporated on October 6, 2013, through its subsidiary ViewRay Technologies, Inc., designs, makes and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Firm offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.